# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Josephine Baker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML049-SYN-TD
- Date: 1969-10-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Colette Ashby-Nwosu, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Seven-month review: antiplatelet plan, blood pressure and screening results. **S**

## History of present illness

Ms. Baker returns five weeks after her preventive visit. She has sung and danced in six concerts over the past month, resting between shows, without chest pain, breathlessness or palpitations, and she has not needed nitroglycerin. Her home blood pressure averages 120/74. She has had no further nosebleeds and no other bleeding. Her screening results: the FIT was negative, the mammogram was normal, and the hepatitis C and HIV tests were negative. The bone density scan showed osteopenia (lowest T-score -1.7 at the femoral neck) with a ten-year fracture risk below the level at which medicine is advised. The optometrist found no disease. She asks how long she must take clopidogrel. **S**

| Element | Detail |
|---|---|
| Performing | Six concerts in a month without symptoms |
| Home blood pressure | Average 120/74 mmHg |
| Screening | FIT, mammogram, hepatitis C and HIV negative; osteopenia below the treatment threshold |
| Seattle Angina Questionnaire-7 | 96 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations or lightheadedness |
| Respiratory | Negative | No breathlessness on stage or on stairs |
| Hematologic/lymphatic | Negative | No bleeding or unusual bruising |
| Musculoskeletal | Negative | Knees stiff after long shows; no falls |

4 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Clopidogrel 75 mg oral tablet: a 600 mg loading dose (eight tablets) 24 hours after the last ticagrelor, then one tablet daily **S**
- Atorvastatin 80 mg oral tablet, one tablet daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet daily **S**
- Lisinopril 10 mg oral tablet, one tablet daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if the pain is not better 5 minutes after the first tablet **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/74 mmHg; pulse 58 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 60.6 kg; BMI 21.5 kg/m². All vital signs are synthetic.

Hemoglobin: 12.4 g/dL; Sodium: 139 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 0.84 mg/dL; eGFR (CKD-EPI 1964): 78 mL/min/1.73 m²; Glucose: 93 mg/dL; Seattle Angina Questionnaire-7 summary: 96. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.2 g/dL at baseline, 12.4 g/dL at this visit **S**
- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 0.82 mg/dL at baseline, 0.84 mg/dL at this visit **S**
- eGFR (CKD-EPI 1964): 81 mL/min/1.73 m² at baseline, 78 mL/min/1.73 m² at this visit **S**
- Glucose: 94 mg/dL at baseline, 93 mg/dL at this visit **S**
- Seattle Angina Questionnaire-7 summary: 70 at baseline, 96 at this visit **S**

## Immunizations given today

- Respiratory syncytial virus vaccine, single dose **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**
- Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 122/74, pulse 58; weight 60.6 kg |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Coronary artery disease, seven months after a non-ST-elevation myocardial infarction** (I25.10). No angina while performing; Seattle Angina Questionnaire-7 96. Hemoglobin 12.4 g/dL on dual antiplatelet therapy. **S**
   - Continue aspirin and clopidogrel until twelve months after the heart attack, then stop clopidogrel and continue aspirin 81 mg alone, as cardiology advised.
   - Continue atorvastatin 80 mg and metoprolol.
   - Next review in about three months, before clopidogrel stops.
2. **High blood pressure** (I10). At goal, 122/74 and 120/74 at home. Potassium 4.5 mmol/L and creatinine 0.84 mg/dL. **S**
   - No change; metabolic panel in six to twelve months.
3. **Absence of the uterus; possible early menopause** (Z90.710). Osteopenia on DXA, below the threshold for medicine. **S**
   - Calcium from food, vitamin D, weight-bearing exercise and balance work; repeat scan in several years.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (seated, average of two readings; home readings) | Every visit | Completed today | 122/74 mmHg; home average 120/74 |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 60.6 kg; six concerts in a month |
| Medication safety | Adherence: aspirin and P2Y12 inhibitor through the dual antiplatelet window, high-intensity statin, beta-blocker, ACE inhibitor | Every visit | Completed today | No missed doses; clopidogrel to stop at twelve months, aspirin to continue |
| Medication safety | Bleeding on dual antiplatelet therapy (symptoms, hemoglobin when indicated) | Every visit | Completed today | No bleeding since the nosebleed in June; hemoglobin 12.4 g/dL, platelets not repeated |
| Laboratory | Metabolic panel (potassium, creatinine, eGFR) on an ACE inhibitor | Every six to twelve months when stable | Completed today | Sodium 139, potassium 4.5, creatinine 0.84 mg/dL (eGFR 78), glucose 93 |
| Laboratory | Lipid panel | Every three to twelve months when stable | Up to date | LDL 62 mg/dL in July; next at about one year |
| Laboratory | Hemoglobin A1c (no diabetes) | Yearly screening | Up to date | 5.6% in April; due at one year |
| Survey | Angina status (Seattle Angina Questionnaire-7) | At intake and every few months in the first year | Completed today | 96 |
| Survey | Depression screen (PHQ-2, then PHQ-9) | After the infarction and periodically | Up to date | PHQ-2 0 at the preventive visit |
| Examination | Stress testing or repeat angiography | Not for routine surveillance | Not indicated | No symptoms; routine repeat testing is not recommended |
| Imaging | Echocardiogram for left ventricular function | After the infarction if not done or if function was reduced; then only with clinical change | Not indicated | No clinical change |
| Examination | Influenza, COVID-19 and RSV vaccination review | Yearly | Completed today | Influenza, COVID-19 and PCV20 at the preventive visit; RSV, zoster dose 1 and Tdap today |
| Self-management | Self-management: chest-pain action plan, nitroglycerin, women's warning symptoms | Every visit | Completed today | Nitroglycerin in the dressing room; not needed |

## Goal progress

- Twelve months of dual antiplatelet therapy from the heart attack without interruption. In progress; target 1970-03-24. **S**
- LDL cholesterol below 70 mg/dL with at least a 50% fall. Outcome by 1969-07-21: LDL 62 mg/dL, a 58% fall from 146. **S**
- Blood pressure below 130/80 mmHg. Outcome by 1969-05-26: 126/78 in the clinic; home average 124/76. **S**
- Complete cardiac rehabilitation and return to performing. Outcome by 1969-07-21: Exercise test to about 10 METs without ischemia; graded return to rehearsals agreed. **S**
- Mood: PHQ-9 below 5 by twelve weeks. Outcome by 1969-07-21: PHQ-9 7 to 3. **S**

## Guideline basis

- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025), American College of Cardiology and American Heart Association (Circulation 2025;151(13):e771-e862)
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026), Aether Forge
- Osteoporosis to Prevent Fractures: Screening (2025), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- RSV vaccine, zoster dose 1 and Tdap given today; second zoster dose in two to six months. Review in about three months, before clopidogrel stops at twelve months. Call 911 for chest pain not relieved five minutes after one nitroglycerin. **S**

